Related Experiment Videos
[Cardiotoxicity of anthracyclines]
M Ferrière1, D Donadio, R Ramirez
1Service de cardiologie, hôpital Saint-Eloi, Montpellier.
Archives Des Maladies Du Coeur Et Des Vaisseaux
|February 1, 1993
Summary
Anthracycline cardiotoxicity limits cancer treatment. Strategies like extended administration and antioxidants (e.g., ICRF 187) reduce cardiac damage, allowing personalized chemotherapy.
Area of Science:
- Oncology
- Cardiology
- Pharmacology
Context:
- Anthracyclines are potent antimitotic antibiotics crucial in cancer therapy.
- Cardiotoxicity is the primary dose-limiting factor for anthracycline use.
- Cardiac damage is irreversible and dose-dependent.
Purpose:
- To explore strategies for mitigating anthracycline-induced cardiotoxicity.
- To investigate methods for early detection and management of cardiac side effects.
- To optimize anthracycline administration for improved therapeutic efficacy and safety.
Summary:
- Cardiac toxicity from anthracyclines stems from oxidative stress in myocytes, distinct from their antitumoral action.
- Extended administration protocols (6-24 hours) reduce cardiotoxicity without compromising efficacy.
- Antioxidants like ICRF 187 show promise in myocardial protection.
- Personalized treatment strategies, including surveillance and tailored dosing, are essential.
Impact:
- Enables higher cumulative anthracycline doses, potentially improving cancer treatment outcomes.
- Reduces the incidence and severity of irreversible cardiotoxicity.
- Facilitates a shift from maximal dosing to individualized patient care.
- Highlights the importance of multidisciplinary collaboration in managing chemotherapy side effects.